Expectations, symptoms, and quality of life before and after 1 year of Pirfenidone treatment in patients with idiopathic pulmonary fibrosis: A single-arm, open-label nonrandomized study.

Dariusz Jastrzebski Sabina Kostorz-Nosal Dagmara GalleAlicja Gałeczka-TurkiewiczJoanna WarzechaSebastian Majewski Wojciech Jerzy Piotrowski Dariusz Ziora

Published in: Health science reports (2023)

One year of antifibrotic treatment resulted in a general improvement in the quality of life per the SF-36 questionnaire. Patients' expectations of disease management did not change; also, access to novel therapies and easy access to health centers specializing in IPF management remained their top needs.

Keyphrases

idiopathic pulmonary fibrosis
open label
end stage renal disease
interstitial lung disease
public health
clinical trial
newly diagnosed
ejection fraction
cross sectional
peritoneal dialysis
radiation therapy
study protocol
patient reported
sleep quality
replacement therapy
rectal cancer